The Promise and Pitfalls of Digital Medication


Publication Title
U.S. Pharmacist
Publication/Creation Date
July 18 2019
Creators/Contributors
Tina Caliendo (creator)
Olga Hilas (creator)
Media Type
Journal Article
Persuasive Intent
Academic
Description
ABSTRACT:

In November 2017, the FDA approved the Abilify MyCite system. This drug-device combination product consists of aripiprazole tablets with an ingestible event marker (IEM) sensor and a wearable sensor patch that detects the signal from the IEM sensor after ingestion, which in turn transmits data to a smartphone application. Patients can use a Web-based portal to allow monitoring by healthcare professionals and caregivers for the purpose of tracking drug ingestion and adherence. Although this new digital technology provides a means to potentially enhance adherence and yield better patient health outcomes, ethical issues may arise for both patients and providers. US Pharm. 2019;44(7):22-24.
HCI Platform
Ingestible
Location on Body
Digestive Tract
Source
https://www.uspharmacist.com/article/the-promise-and-pitfalls-of-digital-medication

Date archived
July 4 2020
Last edited
November 5 2020
How to cite this entry
Tina Caliendo, Olga Hilas. (July 18 2019). "The Promise and Pitfalls of Digital Medication". U.S. Pharmacist. Jobson Medical Information LLC. Fabric of Digital Life. https://fabricofdigitallife.com/Detail/objects/4647